Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-12 4:53 pm Purchase | 2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | ORBIMED ADVISORS LLC | 188,568 8.410% | 50,654 (+36.73%) | Filing History |
| 2021-02-12 4:52 pm Sale | 2020-12-31 | 13G | Inspire Medical Systems, Inc. INSP | ORBIMED ADVISORS LLC | 0 0.000% | -1,347,000 (Position Closed) | Filing History |
| 2021-02-12 4:49 pm Sale | 2020-12-31 | 13G | Harpoon Therapeutics, Inc. HARP | ORBIMED ADVISORS LLC | 102,070 4.020% | -34,000 (-24.99%) | Filing History |
| 2021-02-12 4:48 pm Purchase | 2020-12-31 | 13G | Forte Biosciences, Inc. FBRX | ORBIMED ADVISORS LLC | 25,431 4.740% | 25,431 (New Position) | Filing History |
| 2021-02-12 4:46 pm Purchase | 2020-12-31 | 13G | Standard BioTools Inc. LAB | ORBIMED ADVISORS LLC | 3,499,246 4.720% | 3,499,246 (New Position) | Filing History |
| 2021-02-12 4:44 pm Purchase | 2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 2,753,567 8.360% | 714,285 (+35.03%) | Filing History |
| 2021-02-12 4:41 pm Purchase | 2020-12-31 | 13G | Applied Therapeutics, Inc. APLT | ORBIMED ADVISORS LLC | 1,666,825 7.410% | 817,571 (+96.27%) | Filing History |
| 2021-02-12 4:39 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 200,621 10.250% | 86,000 (+75.03%) | Filing History |
| 2021-02-12 4:37 pm Purchase | 2020-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM | ORBIMED ADVISORS LLC | 484,525 4.970% | 90,116 (+22.85%) | Filing History |
| 2021-02-08 9:54 pm Unchanged | 2021-02-05 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 4,267,564 8.800% | 0 (Unchanged) | Filing History |
| 2021-01-28 8:30 pm Sale | 2021-01-22 | 13D | PREVAIL THERAPEUTICS INC PRVL | ORBIMED ADVISORS LLC | 0 0.000% | -13,822,463 (Position Closed) | Filing History |
| 2021-01-28 1:48 pm Unchanged | 2021-01-26 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 5,947,323 11.200% | 0 (Unchanged) | Filing History |
| 2021-01-21 4:46 pm Purchase | 2021-01-12 | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 29,853,364 9.100% | 29,853,364 (New Position) | Filing History |
| 2021-01-13 5:34 pm Purchase | 2021-01-11 | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 14,847,077 31.900% | 41,700 (+0.28%) | Filing History |
| 2020-12-30 4:27 pm Sale | 2020-12-28 | 13D | Alpine Immune Sciences, Inc. ALPN | ORBIMED ADVISORS LLC | 3,216,206 13.400% | -600,000 (-15.72%) | Filing History |
| 2020-12-11 4:47 pm Purchase | 2020-12-03 | 13D | ARS Pharmaceuticals, Inc. SPRY | ORBIMED ADVISORS LLC | 7,788,511 22.400% | 7,788,511 (New Position) | Filing History |
| 2020-12-11 4:39 pm Purchase | 2020-12-02 | 13D | Kinnate Biopharma Inc. KNTE | ORBIMED ADVISORS LLC | 3,397,929 7.800% | 3,397,929 (New Position) | Filing History |
| 2020-11-20 4:32 pm Unchanged | 2020-11-19 | 13D | Keros Therapeutics, Inc. KROS | ORBIMED ADVISORS LLC | 1,268,734 5.500% | 0 (Unchanged) | Filing History |
| 2020-11-18 2:42 pm Unchanged | 2020-11-17 | 13D | ORIC Pharmaceuticals, Inc. ORIC | ORBIMED ADVISORS LLC | 2,765,717 7.800% | 0 (Unchanged) | Filing History |
| 2020-11-12 5:15 pm Purchase | 2020-11-10 | 13D | Aerpio Pharmaceuticals, Inc. ARPO | ORBIMED ADVISORS LLC | 346,263 11.000% | 346,263 (New Position) | Filing History |